Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review
Background: ATP-competitive tyrosine kinase inhibitors (TKIs) are the current standard of care for patients with chronic phase-chronic myeloid leukemia (CP-CML) in the first-line and second-line (2 L) setting. Treatment after 2 L is not clearly established. Objective: The objective of this study was...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-12-01
|
| Series: | Therapeutic Advances in Hematology |
| Online Access: | https://doi.org/10.1177/20406207221150305 |
| _version_ | 1797389774625964032 |
|---|---|
| author | Ehab Atallah Lovneet Saini Rodrigo Maegawa Tanvi Rajput Regina Corbin Ricardo Viana |
| author_facet | Ehab Atallah Lovneet Saini Rodrigo Maegawa Tanvi Rajput Regina Corbin Ricardo Viana |
| author_sort | Ehab Atallah |
| collection | DOAJ |
| description | Background: ATP-competitive tyrosine kinase inhibitors (TKIs) are the current standard of care for patients with chronic phase-chronic myeloid leukemia (CP-CML) in the first-line and second-line (2 L) setting. Treatment after 2 L is not clearly established. Objective: The objective of this study was to summarize the available evidence to compare the efficacy and safety of interventions in the treatment of CP-CML patients who had received ⩾2 prior TKIs. Design: A systematic literature review was performed. Data source and methods: A systematic literature review (SLR) of studies published until May 2021, reporting clinical outcomes in adult patients with CP-CML who had received ⩾ 2 prior TKIs was performed. Studies were identified through the database searches via Ovid platform (Embase, MEDLINE Epub Ahead of Print, In-Process and Other Non-Indexed Citations, and Cochrane Central Register of Controlled Trials), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), bibliographic search of relevant reviews, and proceedings from the previous 3 years of the key conferences in the field of oncology. Results: Our search identified 38 relevant studies. Among the identified studies of the current third-line treatments, the major molecular response (MMR) rate for ponatinib was 19.0–66.7%, 23.3–25.5% for asciminib, 19.2% for omacetaxine, and 13.2% for bosutinib at 6 months. The complete cytogenetic response (CCyR) rate was 21.4–64.8% for ponatinib, 38.7–40.8% for asciminib, 18–24.2% for bosutinib, and 16.1% for omacetaxine at 6 months. Conclusion: The findings from current SLR demonstrated the lack of data for patients with CML treated with ⩾2 TKIs. TKIs such as asciminib, ponatinib, and bosutinib are valid options for those patients. Further research is needed to identify the best treatment option for patients with CML receiving later lines of therapy. |
| first_indexed | 2024-03-08T23:00:55Z |
| format | Article |
| id | doaj.art-d73c9f284a824493ac980cc0e2b308a3 |
| institution | Directory Open Access Journal |
| issn | 2040-6215 |
| language | English |
| last_indexed | 2024-03-08T23:00:55Z |
| publishDate | 2023-12-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Hematology |
| spelling | doaj.art-d73c9f284a824493ac980cc0e2b308a32023-12-15T21:06:32ZengSAGE PublishingTherapeutic Advances in Hematology2040-62152023-12-011410.1177/20406207221150305Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature reviewEhab AtallahLovneet SainiRodrigo MaegawaTanvi RajputRegina CorbinRicardo VianaBackground: ATP-competitive tyrosine kinase inhibitors (TKIs) are the current standard of care for patients with chronic phase-chronic myeloid leukemia (CP-CML) in the first-line and second-line (2 L) setting. Treatment after 2 L is not clearly established. Objective: The objective of this study was to summarize the available evidence to compare the efficacy and safety of interventions in the treatment of CP-CML patients who had received ⩾2 prior TKIs. Design: A systematic literature review was performed. Data source and methods: A systematic literature review (SLR) of studies published until May 2021, reporting clinical outcomes in adult patients with CP-CML who had received ⩾ 2 prior TKIs was performed. Studies were identified through the database searches via Ovid platform (Embase, MEDLINE Epub Ahead of Print, In-Process and Other Non-Indexed Citations, and Cochrane Central Register of Controlled Trials), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), bibliographic search of relevant reviews, and proceedings from the previous 3 years of the key conferences in the field of oncology. Results: Our search identified 38 relevant studies. Among the identified studies of the current third-line treatments, the major molecular response (MMR) rate for ponatinib was 19.0–66.7%, 23.3–25.5% for asciminib, 19.2% for omacetaxine, and 13.2% for bosutinib at 6 months. The complete cytogenetic response (CCyR) rate was 21.4–64.8% for ponatinib, 38.7–40.8% for asciminib, 18–24.2% for bosutinib, and 16.1% for omacetaxine at 6 months. Conclusion: The findings from current SLR demonstrated the lack of data for patients with CML treated with ⩾2 TKIs. TKIs such as asciminib, ponatinib, and bosutinib are valid options for those patients. Further research is needed to identify the best treatment option for patients with CML receiving later lines of therapy.https://doi.org/10.1177/20406207221150305 |
| spellingShingle | Ehab Atallah Lovneet Saini Rodrigo Maegawa Tanvi Rajput Regina Corbin Ricardo Viana Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review Therapeutic Advances in Hematology |
| title | Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review |
| title_full | Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review |
| title_fullStr | Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review |
| title_full_unstemmed | Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review |
| title_short | Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review |
| title_sort | therapy for patients with chronic phase chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors a systematic literature review |
| url | https://doi.org/10.1177/20406207221150305 |
| work_keys_str_mv | AT ehabatallah therapyforpatientswithchronicphasechronicmyeloidleukemiapreviouslytreatedwith2tyrosinekinaseinhibitorsasystematicliteraturereview AT lovneetsaini therapyforpatientswithchronicphasechronicmyeloidleukemiapreviouslytreatedwith2tyrosinekinaseinhibitorsasystematicliteraturereview AT rodrigomaegawa therapyforpatientswithchronicphasechronicmyeloidleukemiapreviouslytreatedwith2tyrosinekinaseinhibitorsasystematicliteraturereview AT tanvirajput therapyforpatientswithchronicphasechronicmyeloidleukemiapreviouslytreatedwith2tyrosinekinaseinhibitorsasystematicliteraturereview AT reginacorbin therapyforpatientswithchronicphasechronicmyeloidleukemiapreviouslytreatedwith2tyrosinekinaseinhibitorsasystematicliteraturereview AT ricardoviana therapyforpatientswithchronicphasechronicmyeloidleukemiapreviouslytreatedwith2tyrosinekinaseinhibitorsasystematicliteraturereview |